JP2018500896A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018500896A5 JP2018500896A5 JP2017530591A JP2017530591A JP2018500896A5 JP 2018500896 A5 JP2018500896 A5 JP 2018500896A5 JP 2017530591 A JP2017530591 A JP 2017530591A JP 2017530591 A JP2017530591 A JP 2017530591A JP 2018500896 A5 JP2018500896 A5 JP 2018500896A5
- Authority
- JP
- Japan
- Prior art keywords
- rodent
- polypeptide
- gene
- human
- endogenous
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462089549P | 2014-12-09 | 2014-12-09 | |
| US62/089,549 | 2014-12-09 | ||
| US201562106525P | 2015-01-22 | 2015-01-22 | |
| US62/106,525 | 2015-01-22 | ||
| PCT/US2015/064626 WO2016094481A1 (en) | 2014-12-09 | 2015-12-09 | Non-human animals having a humanized cluster of differentiation 274 gene |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020168478A Division JP7145920B2 (ja) | 2014-12-09 | 2020-10-05 | ヒト化分化抗原群２７４遺伝子を有する非ヒト動物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018500896A JP2018500896A (ja) | 2018-01-18 |
| JP2018500896A5 true JP2018500896A5 (enExample) | 2019-01-24 |
Family
ID=55024286
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017530591A Withdrawn JP2018500896A (ja) | 2014-12-09 | 2015-12-09 | ヒト化分化抗原群２７４遺伝子を有する非ヒト動物 |
| JP2020168478A Active JP7145920B2 (ja) | 2014-12-09 | 2020-10-05 | ヒト化分化抗原群２７４遺伝子を有する非ヒト動物 |
| JP2022148949A Active JP7488861B2 (ja) | 2014-12-09 | 2022-09-20 | ヒト化分化抗原群２７４遺伝子を有する非ヒト動物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020168478A Active JP7145920B2 (ja) | 2014-12-09 | 2020-10-05 | ヒト化分化抗原群２７４遺伝子を有する非ヒト動物 |
| JP2022148949A Active JP7488861B2 (ja) | 2014-12-09 | 2022-09-20 | ヒト化分化抗原群２７４遺伝子を有する非ヒト動物 |
Country Status (27)
| Country | Link |
|---|---|
| US (4) | US9913461B2 (enExample) |
| EP (3) | EP3808775B1 (enExample) |
| JP (3) | JP2018500896A (enExample) |
| KR (2) | KR102457921B1 (enExample) |
| CN (2) | CN107257624B (enExample) |
| AU (3) | AU2015360667B2 (enExample) |
| BR (1) | BR112017011982A2 (enExample) |
| CA (1) | CA2968675C (enExample) |
| CY (1) | CY1123723T1 (enExample) |
| DK (2) | DK3230320T3 (enExample) |
| ES (2) | ES2982515T3 (enExample) |
| FI (1) | FI3808775T3 (enExample) |
| HR (2) | HRP20202034T1 (enExample) |
| HU (2) | HUE052606T2 (enExample) |
| IL (3) | IL282649B (enExample) |
| LT (2) | LT3808775T (enExample) |
| MX (1) | MX2017007636A (enExample) |
| NZ (2) | NZ731954A (enExample) |
| PL (1) | PL3808775T3 (enExample) |
| PT (2) | PT3230320T (enExample) |
| RS (2) | RS65664B1 (enExample) |
| RU (1) | RU2711729C2 (enExample) |
| SG (2) | SG11201703931QA (enExample) |
| SI (2) | SI3230320T1 (enExample) |
| SM (2) | SMT202100148T1 (enExample) |
| WO (1) | WO2016094481A1 (enExample) |
| ZA (1) | ZA201703263B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3808775B1 (en) | 2014-12-09 | 2024-04-17 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized cluster of differentiation 274 gene |
| KR102454546B1 (ko) | 2015-11-20 | 2022-10-14 | 리제너론 파마슈티칼스 인코포레이티드 | 인간화 림프구 활성화 유전자 3을 갖는 비인간 동물 |
| EP3411392B1 (en) | 2016-02-04 | 2021-12-29 | Regeneron Pharmaceuticals, Inc. | Non-human animals having an engineered angptl8 gene |
| EP3895529B1 (en) | 2016-02-29 | 2026-04-29 | Regeneron Pharmaceuticals, Inc. | Rodents having a humanized tmprss gene |
| EP3476865B1 (en) * | 2016-06-28 | 2023-09-13 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Method for constructing pd-1 gene-modified humanized animal model and use thereof |
| WO2018041120A1 (en) | 2016-08-31 | 2018-03-08 | Beijing Biocytogen Co., Ltd | Genetically modified non-human animal with human or chimeric tigit |
| CN107815466B (zh) * | 2016-08-31 | 2020-03-13 | 百奥赛图江苏基因生物技术有限公司 | 人源化基因改造动物模型的制备方法及应用 |
| CN107815467B (zh) * | 2016-08-31 | 2021-03-16 | 百奥赛图(北京)医药科技股份有限公司 | 人源化基因改造动物模型的制备方法及应用 |
| WO2018041118A1 (en) | 2016-08-31 | 2018-03-08 | Beijing Biocytogen Co., Ltd | Genetically modified non-human animal with human or chimeric pd-l1 |
| IL324632A (en) | 2016-12-01 | 2026-01-01 | Regeneron Pharma | Radiolabeled anti-PD-L1 antibodies for immuno-PET imaging |
| CN109666701B (zh) * | 2017-10-13 | 2021-08-24 | 百奥赛图(北京)医药科技股份有限公司 | 一种pd-1基因修饰人源化动物模型的构建方法及其应用 |
| WO2019072241A1 (en) | 2017-10-13 | 2019-04-18 | Beijing Biocytogen Co., Ltd | NON-HUMAN ANIMAL GENETICALLY MODIFIED WITH PD-1 HUMAN OR CHIMERIC |
| IL274740B2 (en) | 2017-11-30 | 2024-06-01 | Regeneron Pharma | Non-human animals comprising a humanized trkb locus |
| CN109913493B (zh) | 2017-12-12 | 2021-03-16 | 百奥赛图江苏基因生物技术有限公司 | 人源化cd3基因改造动物模型的制备方法及应用 |
| WO2019190990A1 (en) | 2018-03-26 | 2019-10-03 | Regeneron Pharmaceuticals, Inc. | Humanized rodents for testing therapeutic agents |
| IL315703A (en) | 2018-07-16 | 2024-11-01 | Regeneron Pharma | Non-human animal models of DITRA disease and their uses |
| CN110846321B (zh) * | 2018-08-21 | 2021-11-19 | 中国科学院动物研究所 | 一种突变基因及其用于构建斑色鱼鳞癣小型猪模型的用途 |
| US20210380978A1 (en) * | 2018-10-15 | 2021-12-09 | The Brigham And Women`S Hospital, Inc. | The long non-coding RNA INCA1 and Homo sapiens heterogeneous nuclear ribonucleoprotein H1 (HNRNPH1) as therapeutic targets for immunotherapy |
| CN109452229B (zh) * | 2018-11-19 | 2021-10-22 | 百奥赛图(北京)医药科技股份有限公司 | 狗源化pd-1基因改造动物模型的制备方法及应用 |
| CN109979539B (zh) * | 2019-04-10 | 2020-10-02 | 电子科技大学 | 基因序列优化方法、装置及数据处理终端 |
| CN114621971A (zh) * | 2021-02-19 | 2022-06-14 | 百奥赛图(北京)医药科技股份有限公司 | 经遗传修饰的非人动物及其构建方法和应用 |
| CN112999368A (zh) * | 2021-04-09 | 2021-06-22 | 广东药康生物科技有限公司 | 人源化模型进行药效评价方法的建立 |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5670356A (en) | 1994-12-12 | 1997-09-23 | Promega Corporation | Modified luciferase |
| US6485964B1 (en) * | 1995-03-20 | 2002-11-26 | Arris Pharmaceutical Corporation | Transgenic mammals lacking expression of erythropoietin or of erythropoietin receptor, transgenic mammals expressing chimeric erythropoietin receptors, constructs for producing the transgenic mammals and uses therefor |
| GB9517779D0 (en) | 1995-08-31 | 1995-11-01 | Roslin Inst Edinburgh | Biological manipulation |
| GB9517780D0 (en) | 1995-08-31 | 1995-11-01 | Roslin Inst Edinburgh | Biological manipulation |
| US5874304A (en) | 1996-01-18 | 1999-02-23 | University Of Florida Research Foundation, Inc. | Humanized green fluorescent protein genes and methods |
| EP1320599A2 (en) | 2000-06-28 | 2003-06-25 | Genetics Institute, LLC | Pd-l2 molecules: pd-1 ligands and uses therefor |
| US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US7794710B2 (en) | 2001-04-20 | 2010-09-14 | Mayo Foundation For Medical Education And Research | Methods of enhancing T cell responsiveness |
| DE10211088A1 (de) * | 2002-03-13 | 2003-09-25 | Ugur Sahin | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
| PT1537878E (pt) * | 2002-07-03 | 2010-11-18 | Ono Pharmaceutical Co | Composições de imunopotenciação |
| JP2006517096A (ja) * | 2002-12-16 | 2006-07-20 | ジェネンテック・インコーポレーテッド | ヒトｃｄ２０を発現するトランスジェニックマウス |
| WO2004056875A1 (en) | 2002-12-23 | 2004-07-08 | Wyeth | Antibodies against pd-1 and uses therefor |
| ES2364335T3 (es) * | 2003-12-24 | 2011-08-31 | G2 Inflammation Pty Ltd | Mamífero no humano transgénico que comprende un polinucleótido que codifica el c5ar humano o humanizado. |
| WO2005060739A1 (en) | 2003-12-24 | 2005-07-07 | G2 Inflammation Pty Ltd | Transgenic non-human mammal comprising a polynucleotide encoding human or humanized c5ar |
| DK3428191T3 (da) | 2004-10-06 | 2025-01-02 | Mayo Found Medical Education & Res | B7-h1 og pd-1 til behandling af renalcellekarcinom |
| WO2006044962A1 (en) | 2004-10-19 | 2006-04-27 | Regeneron Pharmaceuticals, Inc. | Method for generating an animal homozygous for a genetic modification |
| CA2612241C (en) * | 2005-07-01 | 2018-11-06 | Medarex, Inc. | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
| EP2468765B1 (en) | 2006-03-03 | 2015-04-22 | ONO Pharmaceutical Co., Ltd. | Tetramer of extracellular domain of PD-L1 |
| PL2342226T3 (pl) | 2008-09-26 | 2017-01-31 | Dana-Farber Cancer Institute, Inc. | Ludzkie przeciwciała anty-PD-1, PD-L1 i PD-L2 oraz ich zastosowania |
| KR101361416B1 (ko) | 2008-10-08 | 2014-02-21 | 인트렉손 코포레이션 | 다수의 면역조절자를 발현하는 조작된 세포 및 그 용도 |
| CA2747534C (en) * | 2008-12-18 | 2020-08-18 | Erasmus University Medical Center Rotterdam | Non-human transgenic animals expressing humanised antibodies and use therof |
| EP3192811A1 (en) | 2009-02-09 | 2017-07-19 | Université d'Aix-Marseille | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
| RU2425880C2 (ru) * | 2009-07-30 | 2011-08-10 | Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН | Способ получения трансгенных мышей |
| US8354389B2 (en) | 2009-08-14 | 2013-01-15 | Regeneron Pharmaceuticals, Inc. | miRNA-regulated differentiation-dependent self-deleting cassette |
| WO2011025962A1 (en) * | 2009-08-28 | 2011-03-03 | Dan Allison | Antikine antibodies that bind to multiple cc chemokines |
| US8541646B2 (en) | 2009-10-06 | 2013-09-24 | Regeneron Pharmaceuticals, Inc. | Genetically modified mice and engraftment |
| WO2011060357A2 (en) | 2009-11-16 | 2011-05-19 | The Ohio State University | Engineered xenogeneic cells for repair of biological tissue |
| NO2504364T3 (enExample) | 2009-11-24 | 2018-01-06 | ||
| NO2516457T3 (enExample) * | 2009-12-21 | 2018-08-11 | ||
| AU2011237630B2 (en) * | 2010-04-06 | 2016-01-21 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of CD274/PD-L1 gene |
| PT4233537T (pt) | 2011-02-15 | 2025-09-08 | Regeneron Pharma | Ratinhos humanizados para m-csf e utilizações dos mesmos |
| PL2818478T3 (pl) | 2011-10-28 | 2017-09-29 | Regeneron Pharmaceuticals, Inc. | Humanizowane il-6 i receptor il-6 |
| RS63220B1 (sr) | 2011-10-28 | 2022-06-30 | Regeneron Pharma | Genetski modifikovani miševi sa ekspresijom himernih molekula klase ii glavnog kompleksa histokompatibilnosti (mhc) |
| ES2741649T3 (es) * | 2011-10-28 | 2020-02-11 | Regeneron Pharma | Ratones con complejo mayor de histocompatibilidad modificado genéticamente |
| EP3696262A1 (en) | 2011-11-23 | 2020-08-19 | The Trustees Of The University Of Pennsylvania | Use of pdl1 expressing cells to convert t cells into regulatory t cells |
| US9624298B2 (en) | 2011-11-28 | 2017-04-18 | Merck Patent Gmbh | Anti-PD-L1 antibodies and uses thereof |
| WO2014022758A1 (en) | 2012-08-03 | 2014-02-06 | Dana-Farber Cancer Institute, Inc. | Single agent anti-pd-l1 and pd-l2 dual binding antibodies and methods of use |
| US20140047572A1 (en) * | 2012-08-13 | 2014-02-13 | University Of Rochester | Thrombopoietin mimetics for the treatment of radiation or chemical induced bone marrow injury |
| IL312711A (en) * | 2012-08-21 | 2024-07-01 | Regeneron Pharma | Methods for the treatment or prevention of asthma through the administration of an antagonist to 4R-IL |
| IN2015DN02032A (enExample) | 2012-09-07 | 2015-08-14 | Univ Yale | |
| ES2884598T3 (es) | 2012-11-05 | 2021-12-10 | Regeneron Pharma | Animales no humanos modificados genéticamente y métodos de uso de los mismos |
| US20140242077A1 (en) | 2013-01-23 | 2014-08-28 | Abbvie, Inc. | Methods and compositions for modulating an immune response |
| US20140235933A1 (en) | 2013-02-20 | 2014-08-21 | Regeneron Pharmaceuticals, Inc. | Genetic modification of rats |
| CA2900832A1 (en) | 2013-02-20 | 2014-08-28 | Regeneron Pharmaceuticals, Inc. | Mice expressing humanized t-cell co-receptors |
| US20150342163A1 (en) | 2013-02-22 | 2015-12-03 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex mice |
| CA2900824A1 (en) | 2013-02-22 | 2014-08-28 | Regeneron Pharmaceuticals, Inc. | Mice expressing humanized major histocompatibility complex |
| DK2986729T3 (en) | 2013-04-16 | 2018-10-29 | Regeneron Pharma | TARGETED MODIFICATION OF ROOT THROUGH |
| CN103242448B (zh) * | 2013-05-27 | 2015-01-14 | 郑州大学 | 一种全人源化抗pd-1单克隆抗体及其制备方法和应用 |
| EP3293275B1 (en) | 2013-06-06 | 2021-08-04 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for identification, assessment prevention, and treatment of cancer using pd-l1 isoforms |
| MX368931B (es) | 2013-09-23 | 2019-10-22 | Regeneron Pharma | Animales no humanos que tienen un gen de proteina reguladora de señal humanizado. |
| US20150143558A1 (en) | 2013-11-19 | 2015-05-21 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized b-cell activating factor gene |
| TWI680138B (zh) * | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| RU2700484C2 (ru) | 2014-04-08 | 2019-09-17 | Регенерон Фармасьютикалз, Инк. | Не относящиеся к человеку животные, имеющие гуманизированные fc-гамма-рецепторы |
| NO2785538T3 (enExample) | 2014-05-07 | 2018-08-04 | ||
| PT3482629T (pt) | 2014-05-19 | 2021-02-18 | Univ Yale | Animais não humanos geneticamente modificados que expressam epo humana |
| EP3683238A1 (en) | 2014-06-19 | 2020-07-22 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized programmed cell death 1 gene |
| KR102659123B1 (ko) | 2014-11-24 | 2024-04-22 | 리제너론 파마슈티칼스 인코포레이티드 | 인간화 cd3 복합체를 발현하는 비인간 동물 |
| FI3850946T3 (fi) | 2014-12-05 | 2023-12-28 | Regeneron Pharma | Ei-ihmiseläimiä, joilla on humanisoitu erilaistumisklusterin 47 geeni |
| EP3808775B1 (en) | 2014-12-09 | 2024-04-17 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized cluster of differentiation 274 gene |
| KR102454546B1 (ko) | 2015-11-20 | 2022-10-14 | 리제너론 파마슈티칼스 인코포레이티드 | 인간화 림프구 활성화 유전자 3을 갖는 비인간 동물 |
| WO2018041118A1 (en) | 2016-08-31 | 2018-03-08 | Beijing Biocytogen Co., Ltd | Genetically modified non-human animal with human or chimeric pd-l1 |
-
2015
- 2015-12-09 EP EP20194168.9A patent/EP3808775B1/en active Active
- 2015-12-09 LT LTEP20194168.9T patent/LT3808775T/lt unknown
- 2015-12-09 CN CN201580067025.6A patent/CN107257624B/zh active Active
- 2015-12-09 RU RU2017123754A patent/RU2711729C2/ru active
- 2015-12-09 HR HRP20202034TT patent/HRP20202034T1/hr unknown
- 2015-12-09 EP EP24167621.2A patent/EP4399969A3/en active Pending
- 2015-12-09 MX MX2017007636A patent/MX2017007636A/es unknown
- 2015-12-09 PT PT158166314T patent/PT3230320T/pt unknown
- 2015-12-09 SG SG11201703931QA patent/SG11201703931QA/en unknown
- 2015-12-09 SG SG10202100792XA patent/SG10202100792XA/en unknown
- 2015-12-09 NZ NZ731954A patent/NZ731954A/en unknown
- 2015-12-09 SM SM20210148T patent/SMT202100148T1/it unknown
- 2015-12-09 FI FIEP20194168.9T patent/FI3808775T3/fi active
- 2015-12-09 US US14/963,402 patent/US9913461B2/en active Active
- 2015-12-09 HU HUE15816631A patent/HUE052606T2/hu unknown
- 2015-12-09 SM SM20240313T patent/SMT202400313T1/it unknown
- 2015-12-09 JP JP2017530591A patent/JP2018500896A/ja not_active Withdrawn
- 2015-12-09 DK DK15816631.4T patent/DK3230320T3/da active
- 2015-12-09 ES ES20194168T patent/ES2982515T3/es active Active
- 2015-12-09 SI SI201531463T patent/SI3230320T1/sl unknown
- 2015-12-09 AU AU2015360667A patent/AU2015360667B2/en active Active
- 2015-12-09 ES ES15816631T patent/ES2841353T3/es active Active
- 2015-12-09 EP EP15816631.4A patent/EP3230320B1/en active Active
- 2015-12-09 RS RS20240717A patent/RS65664B1/sr unknown
- 2015-12-09 IL IL282649A patent/IL282649B/en unknown
- 2015-12-09 LT LTEP15816631.4T patent/LT3230320T/lt unknown
- 2015-12-09 WO PCT/US2015/064626 patent/WO2016094481A1/en not_active Ceased
- 2015-12-09 HR HRP20240855TT patent/HRP20240855T1/hr unknown
- 2015-12-09 DK DK20194168.9T patent/DK3808775T3/da active
- 2015-12-09 SI SI201532021T patent/SI3808775T1/sl unknown
- 2015-12-09 BR BR112017011982A patent/BR112017011982A2/pt not_active Application Discontinuation
- 2015-12-09 PT PT201941689T patent/PT3808775T/pt unknown
- 2015-12-09 NZ NZ770783A patent/NZ770783A/en unknown
- 2015-12-09 CN CN202110688677.9A patent/CN113412818B/zh active Active
- 2015-12-09 RS RS20201547A patent/RS61218B1/sr unknown
- 2015-12-09 CA CA2968675A patent/CA2968675C/en active Active
- 2015-12-09 KR KR1020217033684A patent/KR102457921B1/ko active Active
- 2015-12-09 KR KR1020177016266A patent/KR102316842B1/ko active Active
- 2015-12-09 HU HUE20194168A patent/HUE067123T2/hu unknown
- 2015-12-09 PL PL20194168.9T patent/PL3808775T3/pl unknown
-
2017
- 2017-05-11 ZA ZA2017/03263A patent/ZA201703263B/en unknown
- 2017-06-06 IL IL252695A patent/IL252695B/en active IP Right Grant
-
2018
- 2018-01-30 US US15/883,477 patent/US10881086B2/en active Active
-
2020
- 2020-07-06 IL IL275864A patent/IL275864B/en active IP Right Grant
- 2020-10-05 JP JP2020168478A patent/JP7145920B2/ja active Active
- 2020-12-03 US US17/110,868 patent/US12089575B2/en active Active
- 2020-12-23 CY CY20201101215T patent/CY1123723T1/el unknown
-
2021
- 2021-12-16 AU AU2021286369A patent/AU2021286369B2/en active Active
-
2022
- 2022-09-20 JP JP2022148949A patent/JP7488861B2/ja active Active
-
2024
- 2024-08-15 US US18/805,786 patent/US20240389563A1/en active Pending
-
2025
- 2025-06-24 AU AU2025204751A patent/AU2025204751A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017521060A5 (enExample) | ||
| RU2017123754A (ru) | Не относящиеся к человеку животные, имеющие гуманизированный ген кластера дифференцировки 274 | |
| Tummala et al. | Poly (A)-specific ribonuclease deficiency impacts telomere biology and causes dyskeratosis congenita | |
| KR102617691B1 (ko) | 인간화 분화 클러스터 47 유전자를 가진 비인간 동물 | |
| JP2018533963A5 (enExample) | ||
| RU2016149434A (ru) | Животные, отличные от человека, имеющие гуманизированный ген 1 запрограммированный гибели клеток | |
| JP2018500012A5 (enExample) | ||
| Pravenec et al. | Recent progress in the genetics of spontaneously hypertensive rats | |
| HRP20231121T1 (hr) | Životinje koje nisu ljudi, koje imaju gen za humanizirani protein koji regulira signale | |
| JP2015523863A5 (enExample) | ||
| JP2019505216A5 (enExample) | ||
| JP2018533963A (ja) | ヒト化されたｌｙｍｐｈｏｃｙｔｅ−ａｃｔｉｖａｔｉｏｎ ｇｅｎｅ ３遺伝子を有する非ヒト動物 | |
| IL314733A (en) | Humanized rodents for testing therapeutic agents | |
| EP3585445B1 (en) | Humanized model of kidney and liver disorders | |
| JP2019511918A5 (enExample) | ||
| JP2017213006A5 (enExample) | ||
| US20230413791A1 (en) | Non-human animals having a humanized clec9a gene | |
| Wang et al. | Pno1 tissue-specific expression and its functions related to the immune responses and proteasome activities | |
| JP2023523174A5 (enExample) | ||
| US20220192165A1 (en) | Non-human animals having a humanized tslp gene, a humanized tslp receptor gene, and/or a humanized il7ra gene | |
| US20230146102A1 (en) | Monogenic or polygenic disease model organisms humanized with two or more genes | |
| HK40012890A (en) | Humanized model of kidney and liver disorders | |
| HK40012890B (en) | Humanized model of kidney and liver disorders | |
| NZ765428B2 (en) | Non-human animals having a humanized programmed cell death 1 gene | |
| WO2018100628A1 (ja) | 金属高感度・高感受性の金属アレルギー動物モデルの樹立 |